[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ionclinics & Deionic SL\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100640748","eeg-prediction-and-clinical-efficacy-of-tdcs-in-fibromyalgia-100640748",false,"NCT07583056","EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia.","Clinical Efficacy of tDCS in Fibromyalgia: A Controlled Clinical Trial and Analysis of Electrophysiological Biomarker Predictors.","FM-TDCS-PREDIC","Inclusion Criteria:\n\n* Patients who meet the diagnostic criteria described by the American College of Rheumatology (Wolfe et al., 2016):\n* Widespread Pain Index (WPI) ≥7 and Symptom Severity Scale (SSS) score ≥5 or a WPI score of 4-6 and SSS ≥9\n* Presence of widespread pain, defined as pain in at least 4 of 5 regions. Jaw, chest, and abdominal pain are not included in the definition of widespread pain.\n* Symptoms have been generally present for at least 3 months.\n* The diagnosis of fibromyalgia (FM) is valid regardless of other diagnoses. The diagnosis of FM does not exclude the presence of other clinically significant diseases.\n* Patients with a stable prescription (or lack thereof) for antidepressant\u002Fpharmacological medication and who agree to continue it throughout the study.\n* Demonstrate the ability to properly administer home-based tDCS independently or with the assistance of a caregiver.\n* Have access to an electronic device with a camera (mobile phone or computer) to allow for monitoring of the intervention and communication with the participant.\n* Have the capacity and willingness to commit to the study team for the completion of all phases of the study.\n* Volunteer to participate and sign the specific informed consent form for this study.\n\nExclusion Criteria:\n\n* Presenting with immune system disorders or comorbidities that explain the main symptoms of fibromyalgia: rheumatoid arthritis, lupus, autoimmune, neurological, and oncological disorders.\n* Presenting with any uncompensated clinical condition such as ischemic heart disease, kidney disease, or liver disease.\n* Presenting with dermatological conditions, such as allergic skin reactions at the electrode sites, psoriasis, etc.\n* Any exclusion criteria established by clinical guidelines on non-invasive brain stimulation (Woods et al., 2016):\n* Metallic implants or head injuries, any electronic device such as cochlear implants or cardiac pacemakers.\n* Brain stimulation within the last 6 months.\n* A clinical or family history of epilepsy.\n* Having any structural lesion (for example, any structural neurological condition or more subcortical lesions than would be expected for their age, or having suffered a stroke affecting the stimulated area or connected areas) or any other clinically significant abnormality that could affect safety, participation in the study, or confound the interpretation of the study results, as determined by the investigator.\n* History of drug or alcohol abuse during the study or in the 3 months prior (except for nicotine).\n* Changes in drug treatment in the month prior to starting the trial.\n* Awaiting trial or litigation during the trial.\n* Pregnancy","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its cost-effectiveness, in patients with fibromyalgia.\n\nAs complementary goals, we aim to assess the predictive value of baseline EEG for clinical response to high-dose home-based tDCS treatment; and to describe the effectiveness of a high-dose home-based protocol applied to the motor cortex (M1) versus the dorsolateral prefrontal cortex (DLFPC) in patients with fibromyalgia.",[27],"Fibromyalgia (FM)",[29,30,31,32],"tDCS","Fibromyalgia","EEG","Cost-effectiveness","NOT_YET_RECRUITING","2026-06-03",{"date":36,"type":37},"2026-06-05","ACTUAL",{"date":39,"type":21},"2026-05-15",{"date":41,"type":21},"2028-06-30",{"name":43,"class":44},"Ionclinics & Deionic SL","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100639942","eeg-prediction-and-clinical-efficacy-of-tdcs-in-major-depression-100639942","NCT07611773","EEG Prediction and Clinical Efficacy of tDCS in Major Depression","Clinical Efficacy of tDCS in Major Depression: A Controlled Clinical Trial and Analysis of Electrophysiological Biomarker Predictors","DM-TDCS-PREDIC","Inclusion Criteria:\n\n* Patients aged 18 years or over.\n* Patients diagnosed with Major Depressive Disorder with a current depressive episode, based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Association, 2013).\n* Score on the Hamilton Depression Rating Scale (HDRS-17) ≥16 (Hamilton et al., 1960).\n* Patients on a stable prescription of antidepressants\u002Fpharmacological medication and who agree to continue this throughout the study; and\u002For, if undergoing psychotherapy, who have maintained this treatment consistently for at least 6 weeks.\n* Demonstrate the ability to apply home-based tDCS appropriately, either independently or with the help of a carer.\n* Have access to an electronic device with a camera to enable monitoring of the intervention, as well as to contact the participant.\n* Have the ability and willingness to commit to the study team to complete all phases of the study.\n* Volunteer to participate and sign the specific informed consent form for this study.\n\nExclusion Criteria:\n\n* Patients with a current manic episode as determined by the Young Mania Rating Scale (YMRS), or a psychotic episode as defined by the MINI scale.\n* Patients who answer 'yes' to questions 4, 5 or 6 of the Columbia Suicide Severity Rating Scale (C-SSRS), a risk assessment and identification tool.\n* Patients with treatment-resistant depression, defined as an inadequate clinical response to two or more courses of antidepressant treatment at appropriate doses and duration.\n* Any previous hospitalisation for suicidal behaviour.\n* Presenting with current chronic or severe insomnia (\\\u003C 4 hours' sleep per night) or sleep apnoea.\n* Presence of any structural lesion (e.g., any structural neurological condition or more subcortical lesions than would be expected for their age, or having suffered a stroke affecting the stimulated area or connected areas) or any other clinically significant abnormality that may affect safety, participation in the study, or confound the interpretation of study results, as determined by the investigator.\n* History or presence of any other condition or comorbidity associated with TDM: cardiac or neurological conditions, cognitive impairment.\n* History of or current diagnosis of any other mental disorder: obsessive-compulsive disorder, bipolar disorder (type 1 or 2), anxiety disorder, agoraphobia, eating disorders, personality disorders.\n* Any exclusion criteria other than those established by clinical guidelines on non-invasive brain stimulation (Woods et al., 2016):\n* Metal implants or head injuries, any electronic devices such as cochlear implants or cardiac pacemakers\n* Brain stimulation within the last 6 months.\n* Clinical or family history of epilepsy or seizure episodes.\n* Presence of dermatological problems (allergic skin reaction at the electrode site, psoriasis, etc.)\n* History of drug or alcohol abuse during the study or in the 3 months prior (with the exception of nicotine).\n* Pending trial or litigation during the course of the trial.\n* Pregnancy.",{"count":55,"type":21},270,[24],"The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its cost-effectiveness, in patients with major depression.\n\nAs a secondary aim, we aim to assess the predictive value of baseline EEG for clinical response to high-dose home-based tDCS treatment in patients with major depression.",[59],"Depression - Major Depressive Disorder",[29,61,31,32],"Major depression",{"date":36,"type":37},{"date":64,"type":21},"2026-06-01",{"date":66,"type":21},"2028-12-31",{"name":43,"class":44},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":5},"100632222","home-tdcs-for-the-treatment-of-major-depression-100632222","NCT07510880","Home tDCS for the Treatment of Major Depression.","Home tDCS for the Treatment of Major Depression: A Randomised Clinical Trial","Inclusion Criteria:\n\n* Spanish or Catalan speakers of both sexes between the ages of 18 and 65.\n* Patients diagnosed with major depression, based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Specifically, patients will be included who meet the criteria for a major depressive episode with a longitudinal diagnosis of major depressive disorder, single or recurrent episode; or bipolar disorder type 1 or 2. Patients must obtain a moderate or higher score, therefore we establish a lower limit of 15 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) (Alonzo et al., 2019).\n* Patients receiving or not receiving pharmacological treatment for depression will be included, and this will be recorded as an additional variable.\n* Have the ability and willingness to commit to the study team for supervision of the intervention sessions and close monitoring of safety.\n* Demonstrate the acquisition of the ability to properly apply home tDCS independently or with the help of a companion.\n\nExclusion Criteria:\n\n* Patients with psychotic, schizoaffective, or personality disorders (both cluster A and B).\n* Patients with a history of neurological disease, intellectual disability, or cognitive impairment (inability to understand instructions or operate equipment).\n* Any exclusion criteria established by clinical guidelines on non-invasive brain stimulation (Woods et al., 2016): metal implants or head injuries, any electronic devices such as cochlear implants or cardiac pacemakers. Brain stimulation in the last 6 months. Clinical or family history of epilepsy.\n* Patients with dermatological problems, such as an allergic skin reaction at the electrode site.\n* High risk of suicide. Assessed through an interview with a psychiatrist and the use of the Spanish-validated Columbia Suicide Risk Scale (C-SSRS) (Al-Halabí et al., 2016).\n* Drug or alcohol abuse during the study or in the previous 3 months (except for nicotine).\n* Changes in pharmacological or non-pharmacological treatment (such as structured psychotherapy) during the study or in the 3 months prior to starting the trial.\n* Pregnancy.","65 Years",{"count":77,"type":21},198,[24],"The purpose of this multicentric randomized controlled trial is to compare the effectiveness and safety of home-based tDCS for the treatment of major depression versus tDCS treatment in a healthcare centre, and explore the effects of an accelerated home-tDCS protocol.\n\nThe change in depression index at the end of treatment, measured with MADRS, will be the primary outcome.",[81],"Major Depression Disorder",[83,84,85],"Major Depression","Electric Stimulation Therapy","Transcranial Direct Current Stimulation","RECRUITING","2026-04-27",{"date":89,"type":37},"2026-05-01",{"date":91,"type":37},"2026-04-14",{"date":93,"type":21},"2027-12-31",{"name":43,"class":44},""]